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Background: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are rare neuroendocrine tumors, and
lack of data in Asian populations especially in China. The aim of this retrospective study was to assess the clinical,
pathological and prognostic characteristics of GEP-NENs in China.
Methods: We collected clinical and pathological data of 168 patients diagnosed with GEP-NENs and treated at the
First and Second Affiliated Hospitals of Dalian Medical University between January 2003 and December 2012.
Kaplan-Meier method and log rank analysis was used to analyze the prognostic significance of clinical and
pathological characteristics.
Results: Mean age was 51.83 ± 14.03 and the male-to-female ratio was 1.5:1. Primary sites were the rectum
(58.93%), pancreas (13.69%), stomach (9.52%), duodenum (5.36%), colon (4.76%), appendix (4.76%), ileum
(2.38%) and jejunum (0.60%). Most patients (95.83%) presented non-functional tumors with non-specific
symptoms such as abdominal or back pain (29.17%) and gastrointestinal bleeding (25.60%). Based on the
2010 World Health Organization (WHO) classification, patients were diagnosed with neuroendocrine tumor
(NET) (24.40%) or neuroendocrine carcinoma (NEC) (7.14%). The estimated mean survival was 8.94 ± 0.28 years
(95% CI: 8.40-9.48). Male gender, young age, small tumor size and NET tumor type were favorable prognostic
factors.
Conclusion: Chinese GEP-NENs patients present characteristics that are similar to American and European
patients. However, there is an urgent need to establish a national database for understanding the clinical and
epidemiological features of GEP-NENs in China.
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Neuroendocrine neoplasms (NENs) are epithelial tumors
with a predominant neuroendocrine differentiation, and
they can develop in most organs. This fairly rare neo-
plasms displays a large spectrum of clinical presentations
[1]. According to the Surveillance, Epidemiology and End
results (SEER) database, more than half of all NENs are
gastroenteropancreatic NENs (GEP-NENs) (61%), with the
highest frequency being observed in the rectum (17.7% of* Correspondence: gongpengdalian@163.com
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unless otherwise stated.NENs), small intestine (17.3% of NENs) and colon (10.1%
of NENs), followed by the pancreas (7.0%), stomach
(6.0%), and appendix (3.1%) [2]. The annual incidence of
GEP-NENs is about 3.65-4.7 cases per 100,000 people
in the United States (USA) [2,3]. African Americans
show a higher incidence than Caucasians (6.46 vs. 4.60 per
100,000) [2]. The incidence is also slightly higher in
men compared with women (4.97 vs. 4.49 per 100,000)
[2]. Similar rates were reported in Sweden, Norway, Spain
and England [4-7].
None of the published nomenclatures and classifica-
tions of NENs present a unified classification that is ac-
cepted by clinicians and pathologists [8,9]. In 2010, the
WHO presented a new classification of NENs, in whichLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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crine differentiation. GEP-NENs can be subdivided into
two groups: the well-differentiated neuroendocrine tu-
mors (NETs) and the poorly-differentiated neuroendo-
crine carcinomas (NECs) [10,11]. Furthermore, NETs and
NECs are graded into three types, grades 1 (G1), 2 (G2)
and 3 (G3), according to different definitions of prolifera-
tion using the mitotic count and/or the Ki-67 index [11].
In general, both G1 and G2 NENs are considered as
NETs, and G3 NENs are considered as NECs [11].
Many studies reported the epidemiology, diagnosis, path-
ology and management of GEP-NENs in the American
and the European populations [2,8,12-14], but there is a
lack of data in Asian populations, especially in China.
Therefore, the objective of the present study was to per-
form an epidemiological study of GEP-NENs in a Chinese
population. The present study might provide new clues




We performed a retrospective analysis of all patients
diagnosed with GEP-NENs according to the WHO 2000
classification [15,16] between January 2003 and December
2012 at the First and Second Affiliated Hospitals of Dalian
Medical University.
All patients included in the present study had to have
received a pathological diagnosis of GEP-NENs, and the
original pathology report had to be available. Patients
were excluded if they had received a diagnosis of primary
NENs of any other site, or if the primary NEN site was
unknown. In addition, patients with incomplete records
(clinical and pathological), who were lost to follow-up, or
who refused to participate in our study were also excluded.
The ethics committee of the First Affiliated Hospital of
Dalian Medical University approved the study protocol
(LCKY 2012–32).
Data collection
At the Dalian Medical University, all cancer cases are
prospectively collected into a database. Therefore, the
following variables were collected and analyzed: clinical
characteristics (gender, age, symptoms, signs), diagnostic
procedures (imagery, pathology), tumor characteris-
tics (primary site, size, stage, grading, World Health
Organization (WHO) 2010 classification, WHO 2000
classification), treatments (surgery, hepatic artery inter-
ventional chemotherapy, pharmacotherapy), and follow-
up (date of diagnosis, date of death and cause of death).
Cancer staging was performed using the usual tumor
node metastasis (TNM) approach according to the ana-
tomical sites of the tumors [11,17]. Grading was based on
morphological criteria and tumor proliferative activity.Tumors with a Ki-67 index of ≤ 2% were classified as G1,
3-20% as G2, and > 20% as G3. Similarly, tumors with a
mitotic rate of < 2 per 10 high power fields (HPF) were
classified as G1, 2-20/10 HPF as G2, and > 20/10 HPF as
G3. GEP-NENs were further classified as NET (G1 and
G2), or NEC (G3), according to the 2010 WHO classifica-
tion [10,11].
We performed the final follow-up by telephone, mail
or outpatient department visit in December 2012.
Statistical analysis
All statistical analyses were performed using SPSS 20.0
for Windows (IBM Corporation. Armonk, NY, USA).
We tested continuous variables for normal distribution.
Normally distributed continuous variables are expressed
as mean and standard deviation, and were analyzed
using independent samples t-tests. Categorical variables
are expressed as frequencies and proportions, and were
analyzed using the chi-square test or Fisher’s exact test,
as appropriate. We used the Kaplan-Meier method for
survival analysis, log-rank tests were used for compari-
sion among groups and post hoc analysis for pairwise
comparisons between groups. We performed Cox pro-
portional hazards model to identify independent factors
associated with prognosis. The level of significance was
set at P < 0.05.
Results
Patients’ clinical characteristics
One hundred-sixty-eight patients were included in the
present study. All were Han Chinese and Dalian natives;
102 (61.00%) patients were male, 66 (39.00%) female, and
the male-to-female ratio was 1.5:1. Mean age was 51.83 ±
14.03. The most frequent initial symptoms and signs were
abdominal or back pain (n = 49, 29.17%), followed by
gastrointestinal bleeding (n = 43, 25.60%), dyspepsia (n =
24, 14.29%), and diarrhea (n = 21, 12.50%) (Table 1). Eight
(4.76%) cases were incidental findings during routine
health examinations; these patients were asymptomatic.
Seven (4.16%) patients received a diagnosis of functional
tumors: all of these were insulinomas, and the patients
were hypoglycemic.
Diagnostic procedures
The following procedures were performed at least once
during the diagnosis and management of these tumors:
endoscopy (n = 133, 79.17%), ultrasound (n = 82, 48.81%),
computed tomography (CT) scan (n = 96, 57.14%), and
magnetic resonance imaging (MRI) (n = 17, 10.12%).
The highest positive rate was 97.74% (130/133) for
endoscopy, followed by endoscopic ultrasound (90.00%),
MRI (70.59%), ultrasound (58.54%), and CT (54.17%).
Positron emission computed tomography imaging using
(18 F)-fluoro-deoxy-glucose as tracer (18 F-FDG-PET) was
Table 1 Patients’ characteristics
Male Female Total P -value
N (%) 102 (61.00) 66 (39.00) 168 (100.00)
Age (years) 52.91 ± 13.65 50.15 ± 14.56 51.83 ± 14.03 0.06
Primary tumor site
Gastrointestinal tract 93 (55.36) 52 (30.95) 145 (86.31) 0.02*
Stomach 12 (7.14) 4 (2.38) 16 (9.52) 0.22
Duodenum 6 (3.57) 3 (1.79) 9 (5.36) 1.00
Jejunum 1 (0.60) 0(0.0) 1 (0.60) 1.00
Ileum 3 (1.79) 1 (0.60) 4 (2.38) 1.00
Colon 6 (3.57) 2 (1.19) 8 (4.76) 0.48
Appendix 4 (2.38) 4 (2.38) 8 (4.76) 0.71
Rectum 61 (36.31) 38 (22.62) 99 (58.93) 0.74
Pancreas 9 (5.36) 14 (8.33) 23 (13.69) 0.02*
Clinical Symptoms
Abdominal or back pain 27 (16.07) 22 (13.10) 49 (29.17) 0.33
Gastrointestinal bleedinga 28 (16.67) 15 (8.93) 43 (25.60) 0.49
Dyspepsiab 16 (9.52) 8 (4.76) 24 (14.29) 0.52
Diarrhea 18 (10.71) 3 (1.79) 21 (12.50) 0.12
Tenesmus 13 (7.74) 6 (3.57) 19 (11.31) 0.47
Appetite loss 11 (6.55) 7 (4.17) 18 (10.71) 0.97
Constipation 3 (1.79) 5 (2.98) 8 (4.76) 0.27
Hypoglycemiac 5 (2.98) 2 (1.19) 7 (4.17) 0.71
Weight loss 4 (2.38) 1 (0.60) 5 (2.98) 0.65
Asthenia 1 (0.60) 1 (0.60) 2 (1.19) 1.00
Dysphagia 1 (0.60) 0(0) 1 (0.60) 1.00
Main Signs
Abdominal mass 2 (1.19) 2 (1.19) 4 (2.38) 0.65
Jaundiced 1 (0.60) 1 (0.60) 2 (1.19) 1.00
Rash 1 (0.60) 2 (1.19) 3 (1.79) 0.56
afecal occult blood, bloody stool, hematemesis.
bfullness, bloating, belching, nausea, vomiting.
ctremors, cold sweats, palpitations, hunger, irritability, headache, dizziness, blurred vision, disorientation, coma or seizures.
dskin or sclera.
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three of them, showing a detection rate of 75.00%. Chro-
mogranin A, synaptophysin and neuronspecific enolase
(NSE) are general neuroendocrine markers [18], and were
positive in 72.62%, 76.19%, 32.74% of patients, respectively
(Table 2).
Tumors’ characteristics
As listed in Table 1, the rectum (n = 99, 58.93%) was the
most frequent primary site, followed by the pancreas (n =
23, 13.69%), stomach (n = 16, 9.52%), duodenum (n = 9,
5.36%), colon (n = 8, 4.76%), appendix (n = 8, 4.76%),
ileum (n = 4, 2.38%), and jejunum (n = 1, 0.60%). There
was gender difference in primary tumor site (Table 1).According to the pathology reports of the 168 tumors,
23 specimens were too small to be properly described
(tumor size or extension). The mean size (longest diam-
eter) of the remaining 145 tumors was 2.4 ± 2.3 cm.
At diagnosis, tumor spread was local in 64.29% (n = 108)
of patients, loco-regional in 14.29% (n = 24), and metastatic
in 8.33% (n = 14) (Table 3). The most common site of
distant metastases was the liver (11/14, 78.57%), followed
by the peritoneum (n = 2), and bones (n = 1). Two patients
presented metastatic tumors in the liver accompanied
with brain (n = 1) or ovary (n = 1) metastases. According
to the 2000 WHO classification, 7.14% of GEP-NENs (n =
12) were classified as well-differentiated endocrine tu-
mors, 4.17% (n = 7) were classified as well-differentiated
Table 2 Diagnostic procedures
Cases tested, N (%) Positive, N (%)
Imaging diagnosis
Endoscopy 133 (79.17) 130 (97.74)
Gastroscopy 26 (15.48) 26 (100.00)
Small intestinal endoscopy 11 (6.55) 8 (72.73)
Proctoscopy 96 (57.14) 96 (100.00)
Ultrasound 82 (48.81) 48 (58.54)
Endoscopic ultrasound 20 (11.90) 18 (90.00)
CT 96 (57.14) 52 (54.17)
MRI 17 (10.12) 12 (70.59)
PET-CT 4 (2.38) 3 (75.00)
Immunohistochemistry
Chromogranin A 168 (100) 122 (72.62)
Synaptophysin 168 (100) 128 (76.19)
NSE 168 (100) 55 (32.74)
CT, computed tomography scan; MRI, magnetic resonance imaging; PET-CT,
positron emission computed tomography; NSE, neuron-specific enolase.
Table 3 Tumors’ characteristics
Stomach Duodenum Jejunum Ileum
n = 16 n = 9 n = 1 n = 4
Size
<1 cm 2 0 0 0
1-2 cm 1 4 0 2
>2 cm 9 5 1 2
Unclear 4 0 0 0
Stage
T1N0M0 4 0 0 0
T2N0M0 1 3 0 0
T3N0M0 2 1 0 1
T4N0M0 1 2 0 0
TanyN1M0 5 1 1 3
TanyNanyM1 2 2 0 0
Unclear 1 0 0 0
WHO 2010
NET/G1 0 2 0 0
NET/G2 0 1 0 0
NEC/G3 1 0 0 0
Unclear 15 6 1 4
WHO 2000
WDET 0 2 1 0
WDEC 0 2 0 0
PDEC 1 2 0 0
Unclear 15 3 0 4
TNM: tumor-node-metastasis approach [11]; NET, neuroendocrine tumor; NEC, neuroen
endocrine tumour; WDEC, well differentiated endocrine carcinoma; PDEC, poorly differe
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poorly differentiated endocrine carcinomas. Mitotic rates
were missing in all pathology reports. Most reports (n =
115) did not present morphological criteria and the Ki-67
index. According to the available Ki-67 indexes, 20.23% of
tumors were G1, 4.17% were G2, and 7.14% were G3. The
most common tumor type was NET (n = 41), followed by
NEC (n = 12) (Table 3).
Treatment
Table 4 presents the treatment modalities: 86.90% of
patients underwent surgery. The surgical approach in each
patient was the most optimal one, tailored to each patient’s
disease. Sixteen patients underwent conversion to radical
resection after endoscopic resection. Seven patients had
postoperative complications (intestinal fistula, seroperito-
neum, anastomotic stricture, intestinal obstruction, inci-
sion fat necrosis, and anastomotic fistula), and five patients
had to be reoperated for their complications.
Only 1.79% (n = 3) of patients underwent hepatic trans-
catheter arterial chemoembolization (TACE) to treat liverColon Appendix Rectum Pancreas Total
n = 8 n = 8 n = 99 n = 23 N = 168 (%)
1 0 39 2 44 (26.19)
1 3 31 8 50 (29.76)
5 1 15 13 51 (30.36)
1 4 14 0 23 (13.69)
1 2 43 5 55 (32.74)
0 1 17 5 27 (16.07)
2 4 2 7 19 (11.31)
0 0 0 4 7 (4.17)
3 0 10 1 24 (14.29)
2 1 6 1 14 (7.74)
0 0 21 0 22 (13.69)
1 0 26 5 34 (20.23)
1 0 3 2 7 (4.17)
2 0 4 5 12 (7.14)
4 8 66 11 115 (68.45)
0 0 5 4 12 (7.14)
0 0 5 0 7 (4.17)
0 0 4 6 13 (7.74)
8 8 85 13 136 (80.95)
docrine carcinoma; G1, grade 1; G2, grade 2; G3, grade 3; WDET, well differentiated
ntiated endocrine carcinoma.
Table 4 Treatment modalities
Male Female Total P-
valueN = 102 N = 66 N = 168
Surgery 89 (52.98) 57 (33.93) 146(86.90) 0.87
Laparotomy 69 (41.07) 36 (21.43) 105 (62.50) 0.09
Laparoscopic 3 (1.79) 1 (0.60) 4 (2.38) 1.00
Endoscopic 17 (10.12) 20 (11.90) 37 (22.02) 0.04
TACE 2 (1.19) 1 (0.60) 3 (1.79) 1.00
Pharmacotherapy
Chemotherapy 14 (8.33) 4 (2.38) 18 (10.71) 0.12
Octreotide 12 (7.14) 12 (7.14) 24 (14.29) 0.25
TACE, transcatheter arterial chemoembolization.
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ment in five patients with inoperable tumors, and 13 pa-
tients underwent chemotherapy as postoperative adjuvant
therapy (Table 4). The most commonly used regimen was
FOLFOX4 (oxaliplatin, leucovorin and 5-fluorouracil, n = 7),
followed by oxaliplatin and capecitabine (n = 5), oxalipla-
tin and fluoropyrimidine (n = 1), paclitaxel and carboplatin
(n = 1), docetaxel and gemcitabine (n = 1), cisplatin andTable 5 Overall survival
Number Mean survival times (ye
All 168 8.94 ± 0.28
Age
≤ 50 76 9.50 ± 0.29
> 50 92 7.46 ± 0.38
Gender
Male 102 9.31 ± 0.27
Female 66 7.71 ± 0.61
Site
Rectum 99 9.40 ± 0.27
Pancreas 23 4.09 ± 0.48
Othersa 46 7.59 ± 0.57
Size
< 1 cm 44 9.84 ± 0.16
1-2 cm 50 8.88 ± 0.28
> 2 cm 51 5.06 ± 0.51
Unclearb 23 8.50 ± 0.39
Tumor type
NET 41 7.35 ± 0.63
NEC 12 2.80 ± 0.87
Unclear 115 9.80 ± 0.14
aothers represent stomach, duodenum, jejunum, ileum, colon, appendix.
bspecimens too small to be properly described tumor size.
clog-rank test (pairwise over strata) according to size and tumor type; the P-values o
vs. NEC were < 0.05.
*P <0.05.
NET, neuroendocrine tumor; NEC, neuroendocrine carcinoma.5-fluorouracil (n = 1), streptozotocin and 5-fluorouracil
(n = 1), and taxane and platinum (n = 1). Twenty-four
patients (14.29%) received octreotide, a somatostatin
analogue, as a biological therapy combined with sur-
gery or chemotherapy. Except for endoscopic therapy,
the treatment modality distribution showed no differ-
ence in gender for any other therapies.
Follow-up
The median follow-up was 2.67 years (range: 0.01-
10.00 years). Because of the short follow-up period,
the GEP-NENs’ median survival time was not attained
during the study. At the last follow-up, 14 patients
had died from their GEP-NENs, and 16 patients had
died from accidents or other diseases (cerebral throm-
bosis, lung cancer, myocardial infarction, etc.). The
estimated mean overall survival was 8.94 ± 0.28 years
(95% confidence interval (CI): 8.40-9.48). We analyzed
potential independent survival factors, such as age, gender,
primary tumor site, tumor size, and tumor type (NET
or NEC). As shown in Table 5, survival was significantly
better in young patients, male patients, patients with





















f tumor size 1 cm vs. > 2 cm, 1–2 cm vs. > 2 cm, Unclear vs. > 2 cm and NET
Table 6 Multivariate Cox proportional hazards model
Variable Hazard ratio 95% CI P-value
Age 2.01 1.14-3.56 0.02*
Site 2.94 0.82-10.53 0.10
Size 3.55 0.82-15.47 0.09
Tumor type 2.10 1.02-4.31 0.04*
*P <0.05.
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independent prognostic factors for overall survival (Table 6).
Discussion
The aim of this retrospective study was to assess the
clinical, pathological and prognosis characteristics of GEP-
NENs in China. The rectum, pancreas, stomach and duo-
denum were the most frequent primary sites. The majority
of patients presented non-functional tumors with non-
specific symptoms such as abdominal or back pain and
gastrointestinal bleeding. Based on the 2010 WHO classi-
fication, most patients suffered from NET. The esti-
mated mean survival was relatively short, with 8.94 ±
0.28 years (95% CI: 8.40-9.48). Male gender, young age,
small tumor and NET tumor type were favorable prognos-
tic factors.
NENs may develop anywhere in the body, but most of
them do in the gastrointestinal tract [1]. A large-scale ana-
lysis of GEP-NENs (n = 29,664) from the SEER database
revealed that the highest GEP-NENs frequency was in the
rectum, followed by the small intestine, colon, pancreas,
stomach, and appendix, and that the incidence increased
with years at all primary sites, especially in the rectum and
small intestine [3]. Similarly, we observed that the rectumFigure 1 Kaplan-Meier analyses of different prognostic factors involv
survival by gender; C) Overall survival by site; D) Overall survival by size; E)was the most frequent site of GEP-NENs, followed by the
pancreas, and stomach; however, the small intestine only
accounted for a small proportion of our cases. Neverthe-
less, primary tumor site distribution in the present study
was similar to that of the Korean and Japanese popula-
tions [13,19], suggesting that the distribution of GEP-
NENs’ primary sites may be different between the Asian
and the American populations. However, these observa-
tions might not reflect the true situation. Indeed, guide-
lines recommend that patients over 50 years undergo
colonoscopy when they receive health check at our insti-
tutions, which should increase the early diagnosis rate of
the disease. Meanwhile, with diagnostic improvements,
more and more patients received a diagnosis of appendix
NEN because of an incidental finding of the surgery for aned in GET-NENs prognosis. A) Overall survival by age; B) Overall
Overall survival by tumor type.
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pression that the incidence of GEP-NENs is increasing.
NENs can be classified into functional or nonfunctional
tumors according to the symptoms associated with peptides
and hormones overproduction [20]. The present study
showed that most GEP-NENs in the Chinese population
were nonfunctional tumors. Carcinoid syndrome, Zollinger-
Ellison syndrome, Whipple triad, Verner-Morrison syn-
drome and glucagonoma syndrome are typical symptoms
of functional NENs [21], but no patient showed these
symptoms in the present study. This might be due to two
reasons: 1) clinicians may not pay enough attention to
these symptoms; or 2) NENs were diagnosed at the early
stages, before being symptomatic.
The lack of a uniform nomenclature and classification
system of GEP-NENs prevent the physicians from diag-
nosing and treating these tumors. The WHO updated its
classification in 2010 and accepted the term “GEP-NENs”
[22]. We reviewed the diagnosis process in our participat-
ing institutions. Unfortunately, but as expected, it was not
standardized. The “gold standard” in our participating in-
stitutions was the use of general neuroendocrine markers,
such as chromogranin A, synaptophysin or NSE [23]. We
reviewed the pathology reports of our patients according
to the new WHO 2010 diagnosis and classification cri-
teria, and we observed that 24.40% patients suffered from
NET (n = 41) and 7.14% from NEC (n = 12). Fourteen
patients presented metastases at diagnosis. The total
metastasis rate was 8.33%, which was lower than what was
previously reported [24]. The reasons may be responsible
for regional difference. Unlike other solid tumors, there is
a wide array of therapeutic options, such as surgery, inter-
ventional radiology, systemic therapy, somatostatin ana-
logues, interferon, peptide-receptor radionuclide therapy,
chemotherapy, and targeted agents (sunitinib, everolimus,
bevacizumab) to palliate symptoms and extend survival in
patients with GEP-NENs [25]. As for other tumors, sur-
gery is an essential treatment in many GEP-NENs and is
usually the only way to cure patients. The extent of surgi-
cal resection depends on the extent of the disease (local,
regional or distant metastases). Cytoreductive surgery is
recommended for palliation and to increase survival for
patients with advanced disease [26]. In the present study,
most patients underwent surgery, and only two patients
who underwent surgery died during follow-up.
Chemotherapy is the first treatment option for inoper-
able or metastatic GEP-NENs. The cisplatin and etopo-
side combination is the most widely used chemotherapy
regimen for GEP-NENs [27]. In our cohort, 18 patients
received chemotherapy. The most frequently used chemo-
therapy regimen was the oxaliplatin, leucovorin and 5-
fluorouracil combination.
More and more studies report that biological and targeted
therapies show great promises against NENs. Somatostatinanalogues can reduce the hormone-related symptoms, and
they are an effective therapeutic option for functional neu-
roendocrine tumors [28]. Sunitinib and everolimus may
be used for patients with inoperable locally advanced or
metastatic, progressive, well differentiated pancreatic NENs
[2,29,30]. In the present study, 24 patients underwent som-
atostatin analogues treatment, seven of them suffering
from functional tumors (insulinoma).
The present study suffered from some limitations. The
population’s characteristics (age and gender) presented
in our study are similar to those reported in other stud-
ies of Asian populations [13,19,24,31,32]. However, they
are different from those previously published using the
SEER database or European populations [12,14,33]. Selec-
tion biases among races, populations and hospitals may be
responsible for these differences. Second, the follow-up of
the present study did not reach the median survival time
previously reported. Indeed, our mean survival was 8.94 ±
0.28 years, and was shorter than the 9.5 years reported by
other investigators [24]. This is due to a short follow-up
time and to the slow growing rate of the disease. Third,
the small sample size might have been responsible for
some bias in the multivariate and prognosis analyses.
Fourth, the retrospective nature of the study prevented us
from obtaining some information, such as the Ki-67 index.
In addition, our follow-up system only contains data about
the vital status (alive or not), and not about progression,
preventing us to determine the progression-free survival.
Finally, tumors in the rectum are more easily found at
their early stages by endoscopic examination, while tu-
mors at other sites (e.g. in the pancreas) necessitate exam-
inations that are not routinely performed, which might
affect the incidence.Conclusion
In our study, non-specific clinical symptoms were the
most common symptoms in patients with GEP-NENs.
Diagnosis was mainly based on clinical manifestation,
endoscopy and imagery, as well as on pathology. How-
ever, the recommended morphological criteria and pro-
liferative activity of the tumor were not commonly used
in pathological diagnosis. Surgery was the most common
intervention. Male gender, young age (≤ 50 years), tumor
size (< 2 cm) and NET diagnosis might be favorable prog-
nostic factors. A national database of GEP-NENs should
be established for studying the clinical and epidemio-
logical features of these tumors, and to help physicians
taking better clinical decisions.Consent
Written informed consents were obtained from the pa-
tient for the publication of this report and any accom-
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